Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arena Pharmaceuticals (ARNA) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1468)	3/31/2009 12:40:22 PM
From: scaram(o)uche	Respond to of 2274

Wo! Fenfluramine has been tested in humans since the sixties. Apart from the obesity indication, it has been studied in several blinded trials as an anti-depressant. Lorca is a brave attempt to engineer out the toxicity related to 2A and 2B cross-tickle. All of these cheap-shot analysts are saying: 1. Fenfluramine, minus the heart valve issues, should never have been developed; 2. Fen-phen didn't work; and 3. Obesity is a huge financial burden on society, but elegant attempts to address the issue should be side-swiped with cheap shots. I do agree with his statement "there's bound to be a lot about any agent in this class that we don't know", but why get all paranoid and negative about such, rather than expressing enthusiasm for any potential route to progress?